The FDA’s controversial vaccine chief Vinay Prasad has been abruptly ousted after just three months, amid mounting political pressure over his stance on Sarepta’s gene therapy and COVID vaccine policies. His departure marks a stunning reversal for RFK Jr.’s handpicked regulator, who clashed with both agency scientists and Trump-aligned factions.

The firing follows reports that Trump personally intervened after Prasad publicly criticized Sarepta’s $3.2 million Elevidys therapy, exposing a rift within the administration’s anti-pharma coalition. The move leaves the FDA in turmoil as political battles increasingly dictate public health decisions.

RFK Jr.’s FDA Chief Vinay Prasad Forced Out: Did Trump’s Pressure Over Sarepta’s Gene Therapy Approval Seal His Fate?

The Sudden Ousting of Vinay Prasad: A Political Earthquake at FDA

Dr. Vinay Prasad’s abrupt removal as head of the FDA’s Center for Biologics Evaluation and Research (CBER) after merely three months has sent shockwaves through Washington’s health policy circles. The controversial figure, personally appointed by RFK Jr.’s administration, found himself at the center of a perfect storm – caught between scientific rigor, pharmaceutical interests, and political pressure.

Multiple sources confirm that former President Trump played a direct role in Prasad’s dismissal, particularly following the regulator’s public skepticism about Sarepta Therapeutics’ $3.2 million gene therapy Elevidys. While Prasad shared Trump’s vaccine skepticism, his opposition to accelerated approvals for certain therapies apparently crossed an invisible line.

The timing couldn’t be more suspect – Prasad was reportedly drafting stricter gene therapy guidelines that would have required conventional randomized trials rather than the current accelerated approval pathway favored by pharmaceutical companies. His departure came just days after sending these proposals for internal review.

This wasn’t just about policy differences – it was a raw demonstration of power. Prasad challenged both scientific orthodoxy and corporate interests simultaneously, and Washington showed him the door.

The Sarepta Connection: How a $3.2 Million Therapy Became Prasad’s Downfall

Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy emerged as the flashpoint in Prasad’s brief FDA tenure. Despite mixed clinical trial results and reports of severe adverse events including several pediatric deaths, the therapy received accelerated approval in 2024. Prasad publicly called this decision “scientifically indefensible.”

Behind the scenes, tensions escalated when Prasad:

• Blocked expanded approval for Elevidys in May 2025
• Proposed requiring conventional clinical trials for all gene therapies
• Publicly questioned financial ties between Sarepta and patient advocacy groups

The fallout was immediate. Sarepta’s stock plunged 27% after Prasad’s comments, and pharmaceutical executives reportedly lobbied the White House aggressively. Internal emails show Prasad received warnings about “overstepping” just weeks before his removal.

The gene therapy gold rush can’t tolerate skeptics. When Prasad threatened billions in potential revenue, the industry made sure he wouldn’t get a second term.

RFK Jr. vs Trump: The Hidden Power Struggle Over FDA Control

Prasad’s dismissal exposes deepening fractures within the unorthodox alliance between RFK Jr. and Trump supporters. While both camps promote vaccine skepticism, they differ starkly on pharmaceutical industry oversight. Kennedy reportedly fought to keep Prasad, viewing him as crucial to FDA reform.

The White House’s alleged involvement reveals surprising dynamics:

Kennedy’s public silence since the firing speaks volumes about the political calculus. With the 2026 midterms approaching, alienating both pharmaceutical donors and the anti-vaccine base could prove disastrous.

The Essential Question: Who Really Runs Health Policy?

This episode forces a uncomfortable question about where power truly lies in Washington’s health policy ecosystem. The apparent ease with which pharmaceutical interests leveraged Trump’s influence against Kennedy’s appointee suggests that campaign donations still trump ideology when billions are at stake.

Political leaders come and go, but the pharmaceutical lobby remains Washington’s most persistent force. Prasad learned this lesson the hard way.

The Ripple Effects: What Prasad’s Exit Means for FDA’s Future

Vinay Prasad’s 90-day tenure may have been brief, but its repercussions will likely endure. The firing sends clear signals about the limits of FDA reform:

• Accelerated approvals for gene therapies will likely continue
• Internal FDA resistance to political appointees has strengthened
• The vaccine skeptic movement faces an existential crisis

Most significantly, the episode demonstrates that meaningful FDA reform requires legislative change rather than personnel battles. Acting leadership will likely revert to more conventional regulators, though Kennedy may attempt to install another reformer – albeit one who avoids Prasad’s confrontational style.

The Broader Implications for Science and Democracy

Beyond immediate policy impacts, Prasad’s ouster raises profound questions about the role of science in policymaking. His insistence on rigorous evidence – while popular among researchers – clashed with political and economic realities. The fallout suggests that:

• Scientific rigor increasingly competes with commercial interests
• Accelerated approval pathways may prioritize speed over safety
• Public trust in health agencies continues to erode

The fundamental tension between evidence-based medicine and political expediency appears here to stay. While Prasad’s methods were controversial, his central critique – that financial interests distort scientific judgement – now has fresh evidence supporting it.

This saga isn’t just about one man’s career. It’s about whether science or capital will guide medicine’s future. Right now, the scoreboard doesn’t favor the scientists.

Conclusion: A Watershed Moment for FDA and Health Policy

The Vinay Prasad episode represents more than a personnel change—it’s a case study in power dynamics. For those hoping to reform the FDA, the lessons are clear: lasting change requires congressional action rather than relying on maverick appointees. The pharmaceutical industry’s ability to influence outcomes, even against a theoretically sympathetic administration, should concern advocates on all sides.

As the dust settles, three key questions remain:

1. Will RFK Jr. attempt to install another reform-minded FDA leader?
2. How will this affect public trust in gene therapies and other novel treatments?
3. Does this mark the end of the Trump-Kennedy alliance on health policy?

History may remember Prasad not for his policies, but for revealing how the system really works when challenged. That revelation alone could prove transformative in the long run.